Investigational drug · Phase 2
OSE-279
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer).
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "OSE-279"
First trial start
2022
Dec 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OSE-279", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Advanced Tumor
- Lymphoma
- NSCLC (Non-small Cell Lung Cancer)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "OSE-279" as an intervention, largest first.
- Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasRecruiting
OSE ImmunotherapeuticsIndustry
NCT05751798 · 41 participants (planned) · Start Dec 20, 2022 · Primary completion Dec 2029
Drug: Part A: OSE-279 100mg; Part A: OSE-279 300mg and 5 more · For: Solid Advanced Tumor; Lymphoma; NSCLC (Non-small Cell Lung Cancer)
Sites: Anderlecht, Belgium; Edegem, Belgium; Lyon, France · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
Robert M, Kotecki N, Gomez-Roca C, et al. · Eur J Cancer 2026
Also in development for Solid Advanced Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.